Lilly's Foundayo Outperforms Oral Semaglutide in Type 2 Diabetes Trials, FDA Submission Planned
LLY sits 86% above its 52-week low of $623.78.
Summary
Eli Lilly's Foundayo demonstrated superior A1C control and weight loss in three pivotal Type 2 Diabetes trials, significantly outperforming oral semaglutide. The 17.2 mg dose lowered A1C by 2.2% compared to 1.4% for oral semaglutide and achieved 73.6% greater weight loss. This strong efficacy data against a key competitor positions Foundayo favorably in the lucrative Type 2 Diabetes market, building on its existing FDA approval for weight loss. The company plans to submit Foundayo for Type 2 Diabetes to the U.S. FDA by the end of Q2.
At the time of this announcement, LLY was trading at $1,158.35 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.